nodes	percent_of_prediction	percent_of_DWPC	metapath
Solifenacin—Obstructive airways disorder—Methotrexate—muscle cancer	0.0344	0.0344	CcSEcCtD
Solifenacin—Faecaloma—Doxorubicin—muscle cancer	0.0237	0.0237	CcSEcCtD
Solifenacin—Faecalith—Doxorubicin—muscle cancer	0.0237	0.0237	CcSEcCtD
Solifenacin—Intestinal obstruction—Vincristine—muscle cancer	0.0236	0.0236	CcSEcCtD
Solifenacin—Ileus—Vincristine—muscle cancer	0.0227	0.0227	CcSEcCtD
Solifenacin—Drug interaction—Vincristine—muscle cancer	0.0174	0.0174	CcSEcCtD
Solifenacin—Liver function test abnormal—Dactinomycin—muscle cancer	0.0121	0.0121	CcSEcCtD
Solifenacin—Liver disorder—Methotrexate—muscle cancer	0.0115	0.0115	CcSEcCtD
Solifenacin—Urinary retention—Vincristine—muscle cancer	0.0111	0.0111	CcSEcCtD
Solifenacin—Muscular weakness—Vincristine—muscle cancer	0.0103	0.0103	CcSEcCtD
Solifenacin—Ileus—Doxorubicin—muscle cancer	0.00956	0.00956	CcSEcCtD
Solifenacin—Dysuria—Vincristine—muscle cancer	0.00944	0.00944	CcSEcCtD
Solifenacin—Pharyngitis—Dactinomycin—muscle cancer	0.00898	0.00898	CcSEcCtD
Solifenacin—Depression—Vincristine—muscle cancer	0.00898	0.00898	CcSEcCtD
Solifenacin—Erythema multiforme—Dactinomycin—muscle cancer	0.00856	0.00856	CcSEcCtD
Solifenacin—Dysphonia—Doxorubicin—muscle cancer	0.00822	0.00822	CcSEcCtD
Solifenacin—Hallucination—Vincristine—muscle cancer	0.00804	0.00804	CcSEcCtD
Solifenacin—Urinary tract disorder—Vincristine—muscle cancer	0.00798	0.00798	CcSEcCtD
Solifenacin—Connective tissue disorder—Vincristine—muscle cancer	0.00794	0.00794	CcSEcCtD
Solifenacin—Urethral disorder—Vincristine—muscle cancer	0.00792	0.00792	CcSEcCtD
Solifenacin—Delirium—Doxorubicin—muscle cancer	0.00786	0.00786	CcSEcCtD
Solifenacin—Cystitis noninfective—Methotrexate—muscle cancer	0.00763	0.00763	CcSEcCtD
Solifenacin—Cystitis—Methotrexate—muscle cancer	0.00754	0.00754	CcSEcCtD
Solifenacin—Cardiac disorder—Vincristine—muscle cancer	0.0075	0.0075	CcSEcCtD
Solifenacin—Angiopathy—Vincristine—muscle cancer	0.00733	0.00733	CcSEcCtD
Solifenacin—Infestation NOS—Etoposide—muscle cancer	0.00729	0.00729	CcSEcCtD
Solifenacin—Infestation—Etoposide—muscle cancer	0.00729	0.00729	CcSEcCtD
Solifenacin—Mediastinal disorder—Vincristine—muscle cancer	0.00729	0.00729	CcSEcCtD
Solifenacin—Renal failure—Etoposide—muscle cancer	0.00717	0.00717	CcSEcCtD
Solifenacin—Mental disorder—Vincristine—muscle cancer	0.00708	0.00708	CcSEcCtD
Solifenacin—Bladder pain—Methotrexate—muscle cancer	0.00706	0.00706	CcSEcCtD
Solifenacin—Hepatobiliary disease—Etoposide—muscle cancer	0.0069	0.0069	CcSEcCtD
Solifenacin—Hepatocellular injury—Doxorubicin—muscle cancer	0.00676	0.00676	CcSEcCtD
Solifenacin—Hyperkalaemia—Doxorubicin—muscle cancer	0.00665	0.00665	CcSEcCtD
Solifenacin—Cystitis noninfective—Doxorubicin—muscle cancer	0.00661	0.00661	CcSEcCtD
Solifenacin—Cystitis—Doxorubicin—muscle cancer	0.00653	0.00653	CcSEcCtD
Solifenacin—Urinary tract disorder—Etoposide—muscle cancer	0.00647	0.00647	CcSEcCtD
Solifenacin—Urethral disorder—Etoposide—muscle cancer	0.00642	0.00642	CcSEcCtD
Solifenacin—Infection—Dactinomycin—muscle cancer	0.00639	0.00639	CcSEcCtD
Solifenacin—Dry eye—Doxorubicin—muscle cancer	0.00625	0.00625	CcSEcCtD
Solifenacin—Erythema multiforme—Etoposide—muscle cancer	0.00619	0.00619	CcSEcCtD
Solifenacin—Eye disorder—Etoposide—muscle cancer	0.00612	0.00612	CcSEcCtD
Solifenacin—Bladder pain—Doxorubicin—muscle cancer	0.00612	0.00612	CcSEcCtD
Solifenacin—Cardiac disorder—Etoposide—muscle cancer	0.00608	0.00608	CcSEcCtD
Solifenacin—Hypertension—Vincristine—muscle cancer	0.00608	0.00608	CcSEcCtD
Solifenacin—Dermatitis exfoliative—Methotrexate—muscle cancer	0.00601	0.00601	CcSEcCtD
Solifenacin—Angiopathy—Etoposide—muscle cancer	0.00594	0.00594	CcSEcCtD
Solifenacin—Immune system disorder—Etoposide—muscle cancer	0.00592	0.00592	CcSEcCtD
Solifenacin—Mediastinal disorder—Etoposide—muscle cancer	0.0059	0.0059	CcSEcCtD
Solifenacin—Anaphylactic shock—Vincristine—muscle cancer	0.00574	0.00574	CcSEcCtD
Solifenacin—Infection—Vincristine—muscle cancer	0.00571	0.00571	CcSEcCtD
Solifenacin—Nervous system disorder—Vincristine—muscle cancer	0.00563	0.00563	CcSEcCtD
Solifenacin—Decreased appetite—Dactinomycin—muscle cancer	0.00559	0.00559	CcSEcCtD
Solifenacin—Dysgeusia—Etoposide—muscle cancer	0.00558	0.00558	CcSEcCtD
Solifenacin—Fatigue—Dactinomycin—muscle cancer	0.00554	0.00554	CcSEcCtD
Solifenacin—Feeling abnormal—Dactinomycin—muscle cancer	0.0053	0.0053	CcSEcCtD
Solifenacin—Gastrointestinal pain—Dactinomycin—muscle cancer	0.00526	0.00526	CcSEcCtD
Solifenacin—Liver function test abnormal—Methotrexate—muscle cancer	0.00523	0.00523	CcSEcCtD
Solifenacin—Dermatitis exfoliative—Doxorubicin—muscle cancer	0.0052	0.0052	CcSEcCtD
Solifenacin—Renal impairment—Doxorubicin—muscle cancer	0.00516	0.00516	CcSEcCtD
Solifenacin—Abdominal pain—Dactinomycin—muscle cancer	0.00508	0.00508	CcSEcCtD
Solifenacin—Decreased appetite—Vincristine—muscle cancer	0.00499	0.00499	CcSEcCtD
Solifenacin—Cough—Etoposide—muscle cancer	0.00497	0.00497	CcSEcCtD
Solifenacin—Gastrointestinal disorder—Vincristine—muscle cancer	0.00496	0.00496	CcSEcCtD
Solifenacin—Fatigue—Vincristine—muscle cancer	0.00495	0.00495	CcSEcCtD
Solifenacin—Hypertension—Etoposide—muscle cancer	0.00492	0.00492	CcSEcCtD
Solifenacin—Constipation—Vincristine—muscle cancer	0.00491	0.00491	CcSEcCtD
Solifenacin—Unspecified disorder of skin and subcutaneous tissue—Etoposide—muscle cancer	0.00482	0.00482	CcSEcCtD
Solifenacin—Hypersensitivity—Dactinomycin—muscle cancer	0.00474	0.00474	CcSEcCtD
Solifenacin—Gastrointestinal pain—Vincristine—muscle cancer	0.0047	0.0047	CcSEcCtD
Solifenacin—Confusional state—Etoposide—muscle cancer	0.00469	0.00469	CcSEcCtD
Solifenacin—Anaphylactic shock—Etoposide—muscle cancer	0.00465	0.00465	CcSEcCtD
Solifenacin—Infection—Etoposide—muscle cancer	0.00462	0.00462	CcSEcCtD
Solifenacin—Asthenia—Dactinomycin—muscle cancer	0.00461	0.00461	CcSEcCtD
Solifenacin—Dysuria—Methotrexate—muscle cancer	0.00458	0.00458	CcSEcCtD
Solifenacin—Tachycardia—Etoposide—muscle cancer	0.00454	0.00454	CcSEcCtD
Solifenacin—Abdominal pain—Vincristine—muscle cancer	0.00454	0.00454	CcSEcCtD
Solifenacin—Liver function test abnormal—Doxorubicin—muscle cancer	0.00453	0.00453	CcSEcCtD
Solifenacin—Skin disorder—Etoposide—muscle cancer	0.00452	0.00452	CcSEcCtD
Solifenacin—Dry skin—Doxorubicin—muscle cancer	0.0045	0.0045	CcSEcCtD
Solifenacin—Abdominal pain upper—Doxorubicin—muscle cancer	0.00448	0.00448	CcSEcCtD
Solifenacin—Infestation NOS—Methotrexate—muscle cancer	0.00437	0.00437	CcSEcCtD
Solifenacin—Infestation—Methotrexate—muscle cancer	0.00437	0.00437	CcSEcCtD
Solifenacin—Depression—Methotrexate—muscle cancer	0.00436	0.00436	CcSEcCtD
Solifenacin—Muscular weakness—Doxorubicin—muscle cancer	0.00433	0.00433	CcSEcCtD
Solifenacin—Renal failure—Methotrexate—muscle cancer	0.0043	0.0043	CcSEcCtD
Solifenacin—Influenza—Doxorubicin—muscle cancer	0.00424	0.00424	CcSEcCtD
Solifenacin—Hypersensitivity—Vincristine—muscle cancer	0.00423	0.00423	CcSEcCtD
Solifenacin—Somnolence—Etoposide—muscle cancer	0.00414	0.00414	CcSEcCtD
Solifenacin—Hepatobiliary disease—Methotrexate—muscle cancer	0.00413	0.00413	CcSEcCtD
Solifenacin—Asthenia—Vincristine—muscle cancer	0.00412	0.00412	CcSEcCtD
Solifenacin—Vomiting—Dactinomycin—muscle cancer	0.00409	0.00409	CcSEcCtD
Solifenacin—Rash—Dactinomycin—muscle cancer	0.00405	0.00405	CcSEcCtD
Solifenacin—Decreased appetite—Etoposide—muscle cancer	0.00404	0.00404	CcSEcCtD
Solifenacin—Gastrointestinal disorder—Etoposide—muscle cancer	0.00402	0.00402	CcSEcCtD
Solifenacin—Fatigue—Etoposide—muscle cancer	0.00401	0.00401	CcSEcCtD
Solifenacin—Constipation—Etoposide—muscle cancer	0.00398	0.00398	CcSEcCtD
Solifenacin—Dysuria—Doxorubicin—muscle cancer	0.00397	0.00397	CcSEcCtD
Solifenacin—Pharyngitis—Methotrexate—muscle cancer	0.00389	0.00389	CcSEcCtD
Solifenacin—Urinary tract disorder—Methotrexate—muscle cancer	0.00387	0.00387	CcSEcCtD
Solifenacin—Urethral disorder—Methotrexate—muscle cancer	0.00385	0.00385	CcSEcCtD
Solifenacin—Feeling abnormal—Etoposide—muscle cancer	0.00383	0.00383	CcSEcCtD
Solifenacin—Nausea—Dactinomycin—muscle cancer	0.00382	0.00382	CcSEcCtD
Solifenacin—Gastrointestinal pain—Etoposide—muscle cancer	0.0038	0.0038	CcSEcCtD
Solifenacin—Dizziness—Vincristine—muscle cancer	0.0038	0.0038	CcSEcCtD
Solifenacin—Infestation NOS—Doxorubicin—muscle cancer	0.00378	0.00378	CcSEcCtD
Solifenacin—Infestation—Doxorubicin—muscle cancer	0.00378	0.00378	CcSEcCtD
Solifenacin—Renal failure—Doxorubicin—muscle cancer	0.00372	0.00372	CcSEcCtD
Solifenacin—Erythema multiforme—Methotrexate—muscle cancer	0.00371	0.00371	CcSEcCtD
Solifenacin—Urticaria—Etoposide—muscle cancer	0.0037	0.0037	CcSEcCtD
Solifenacin—Abdominal pain—Etoposide—muscle cancer	0.00368	0.00368	CcSEcCtD
Solifenacin—Urinary tract infection—Doxorubicin—muscle cancer	0.00368	0.00368	CcSEcCtD
Solifenacin—Eye disorder—Methotrexate—muscle cancer	0.00367	0.00367	CcSEcCtD
Solifenacin—Vomiting—Vincristine—muscle cancer	0.00365	0.00365	CcSEcCtD
Solifenacin—Cardiac disorder—Methotrexate—muscle cancer	0.00364	0.00364	CcSEcCtD
Solifenacin—Rash—Vincristine—muscle cancer	0.00362	0.00362	CcSEcCtD
Solifenacin—Dermatitis—Vincristine—muscle cancer	0.00362	0.00362	CcSEcCtD
Solifenacin—Headache—Vincristine—muscle cancer	0.0036	0.0036	CcSEcCtD
Solifenacin—Hepatobiliary disease—Doxorubicin—muscle cancer	0.00358	0.00358	CcSEcCtD
Solifenacin—Angiopathy—Methotrexate—muscle cancer	0.00356	0.00356	CcSEcCtD
Solifenacin—Immune system disorder—Methotrexate—muscle cancer	0.00354	0.00354	CcSEcCtD
Solifenacin—Mediastinal disorder—Methotrexate—muscle cancer	0.00354	0.00354	CcSEcCtD
Solifenacin—Mental disorder—Methotrexate—muscle cancer	0.00344	0.00344	CcSEcCtD
Solifenacin—Hypersensitivity—Etoposide—muscle cancer	0.00343	0.00343	CcSEcCtD
Solifenacin—Malnutrition—Methotrexate—muscle cancer	0.00341	0.00341	CcSEcCtD
Solifenacin—Nausea—Vincristine—muscle cancer	0.00341	0.00341	CcSEcCtD
Solifenacin—Pharyngitis—Doxorubicin—muscle cancer	0.00337	0.00337	CcSEcCtD
Solifenacin—Urinary tract disorder—Doxorubicin—muscle cancer	0.00335	0.00335	CcSEcCtD
Solifenacin—Oedema peripheral—Doxorubicin—muscle cancer	0.00335	0.00335	CcSEcCtD
Solifenacin—Dysgeusia—Methotrexate—muscle cancer	0.00334	0.00334	CcSEcCtD
Solifenacin—Asthenia—Etoposide—muscle cancer	0.00334	0.00334	CcSEcCtD
Solifenacin—Connective tissue disorder—Doxorubicin—muscle cancer	0.00334	0.00334	CcSEcCtD
Solifenacin—Urethral disorder—Doxorubicin—muscle cancer	0.00333	0.00333	CcSEcCtD
Solifenacin—Pruritus—Etoposide—muscle cancer	0.00329	0.00329	CcSEcCtD
Solifenacin—Vision blurred—Methotrexate—muscle cancer	0.00322	0.00322	CcSEcCtD
Solifenacin—Erythema multiforme—Doxorubicin—muscle cancer	0.00321	0.00321	CcSEcCtD
Solifenacin—Eye disorder—Doxorubicin—muscle cancer	0.00317	0.00317	CcSEcCtD
Solifenacin—Cardiac disorder—Doxorubicin—muscle cancer	0.00315	0.00315	CcSEcCtD
Solifenacin—Angiopathy—Doxorubicin—muscle cancer	0.00308	0.00308	CcSEcCtD
Solifenacin—Dizziness—Etoposide—muscle cancer	0.00308	0.00308	CcSEcCtD
Solifenacin—Immune system disorder—Doxorubicin—muscle cancer	0.00307	0.00307	CcSEcCtD
Solifenacin—Mediastinal disorder—Doxorubicin—muscle cancer	0.00306	0.00306	CcSEcCtD
Solifenacin—Cough—Methotrexate—muscle cancer	0.00298	0.00298	CcSEcCtD
Solifenacin—Mental disorder—Doxorubicin—muscle cancer	0.00298	0.00298	CcSEcCtD
Solifenacin—Vomiting—Etoposide—muscle cancer	0.00296	0.00296	CcSEcCtD
Solifenacin—Malnutrition—Doxorubicin—muscle cancer	0.00296	0.00296	CcSEcCtD
Solifenacin—Rash—Etoposide—muscle cancer	0.00293	0.00293	CcSEcCtD
Solifenacin—Dermatitis—Etoposide—muscle cancer	0.00293	0.00293	CcSEcCtD
Solifenacin—Headache—Etoposide—muscle cancer	0.00291	0.00291	CcSEcCtD
Solifenacin—Dysgeusia—Doxorubicin—muscle cancer	0.0029	0.0029	CcSEcCtD
Solifenacin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—muscle cancer	0.00289	0.00289	CcSEcCtD
Solifenacin—Confusional state—Methotrexate—muscle cancer	0.00281	0.00281	CcSEcCtD
Solifenacin—Anaphylactic shock—Methotrexate—muscle cancer	0.00279	0.00279	CcSEcCtD
Solifenacin—Vision blurred—Doxorubicin—muscle cancer	0.00279	0.00279	CcSEcCtD
Solifenacin—Infection—Methotrexate—muscle cancer	0.00277	0.00277	CcSEcCtD
Solifenacin—Nausea—Etoposide—muscle cancer	0.00276	0.00276	CcSEcCtD
Solifenacin—Nervous system disorder—Methotrexate—muscle cancer	0.00273	0.00273	CcSEcCtD
Solifenacin—Skin disorder—Methotrexate—muscle cancer	0.00271	0.00271	CcSEcCtD
Solifenacin—Palpitations—Doxorubicin—muscle cancer	0.00261	0.00261	CcSEcCtD
Solifenacin—Cough—Doxorubicin—muscle cancer	0.00258	0.00258	CcSEcCtD
Solifenacin—Hypertension—Doxorubicin—muscle cancer	0.00255	0.00255	CcSEcCtD
Solifenacin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—muscle cancer	0.0025	0.0025	CcSEcCtD
Solifenacin—Somnolence—Methotrexate—muscle cancer	0.00248	0.00248	CcSEcCtD
Solifenacin—Dry mouth—Doxorubicin—muscle cancer	0.00246	0.00246	CcSEcCtD
Solifenacin—Dyspepsia—Methotrexate—muscle cancer	0.00245	0.00245	CcSEcCtD
Solifenacin—Confusional state—Doxorubicin—muscle cancer	0.00243	0.00243	CcSEcCtD
Solifenacin—Decreased appetite—Methotrexate—muscle cancer	0.00242	0.00242	CcSEcCtD
Solifenacin—Anaphylactic shock—Doxorubicin—muscle cancer	0.00241	0.00241	CcSEcCtD
Solifenacin—Gastrointestinal disorder—Methotrexate—muscle cancer	0.00241	0.00241	CcSEcCtD
Solifenacin—Fatigue—Methotrexate—muscle cancer	0.0024	0.0024	CcSEcCtD
Solifenacin—Infection—Doxorubicin—muscle cancer	0.0024	0.0024	CcSEcCtD
Solifenacin—Nervous system disorder—Doxorubicin—muscle cancer	0.00237	0.00237	CcSEcCtD
Solifenacin—Tachycardia—Doxorubicin—muscle cancer	0.00236	0.00236	CcSEcCtD
Solifenacin—Skin disorder—Doxorubicin—muscle cancer	0.00234	0.00234	CcSEcCtD
Solifenacin—Feeling abnormal—Methotrexate—muscle cancer	0.0023	0.0023	CcSEcCtD
Solifenacin—Gastrointestinal pain—Methotrexate—muscle cancer	0.00228	0.00228	CcSEcCtD
Solifenacin—Urticaria—Methotrexate—muscle cancer	0.00221	0.00221	CcSEcCtD
Solifenacin—Abdominal pain—Methotrexate—muscle cancer	0.0022	0.0022	CcSEcCtD
Solifenacin—Somnolence—Doxorubicin—muscle cancer	0.00215	0.00215	CcSEcCtD
Solifenacin—Dyspepsia—Doxorubicin—muscle cancer	0.00212	0.00212	CcSEcCtD
Solifenacin—Decreased appetite—Doxorubicin—muscle cancer	0.0021	0.0021	CcSEcCtD
Solifenacin—Gastrointestinal disorder—Doxorubicin—muscle cancer	0.00208	0.00208	CcSEcCtD
Solifenacin—Fatigue—Doxorubicin—muscle cancer	0.00208	0.00208	CcSEcCtD
Solifenacin—Constipation—Doxorubicin—muscle cancer	0.00206	0.00206	CcSEcCtD
Solifenacin—Hypersensitivity—Methotrexate—muscle cancer	0.00205	0.00205	CcSEcCtD
Solifenacin—Asthenia—Methotrexate—muscle cancer	0.002	0.002	CcSEcCtD
Solifenacin—Feeling abnormal—Doxorubicin—muscle cancer	0.00199	0.00199	CcSEcCtD
Solifenacin—Gastrointestinal pain—Doxorubicin—muscle cancer	0.00197	0.00197	CcSEcCtD
Solifenacin—Pruritus—Methotrexate—muscle cancer	0.00197	0.00197	CcSEcCtD
Solifenacin—Urticaria—Doxorubicin—muscle cancer	0.00192	0.00192	CcSEcCtD
Solifenacin—Abdominal pain—Doxorubicin—muscle cancer	0.00191	0.00191	CcSEcCtD
Solifenacin—Dizziness—Methotrexate—muscle cancer	0.00184	0.00184	CcSEcCtD
Solifenacin—Hypersensitivity—Doxorubicin—muscle cancer	0.00178	0.00178	CcSEcCtD
Solifenacin—Vomiting—Methotrexate—muscle cancer	0.00177	0.00177	CcSEcCtD
Solifenacin—Rash—Methotrexate—muscle cancer	0.00176	0.00176	CcSEcCtD
Solifenacin—Dermatitis—Methotrexate—muscle cancer	0.00176	0.00176	CcSEcCtD
Solifenacin—Headache—Methotrexate—muscle cancer	0.00175	0.00175	CcSEcCtD
Solifenacin—Asthenia—Doxorubicin—muscle cancer	0.00173	0.00173	CcSEcCtD
Solifenacin—Pruritus—Doxorubicin—muscle cancer	0.00171	0.00171	CcSEcCtD
Solifenacin—Nausea—Methotrexate—muscle cancer	0.00166	0.00166	CcSEcCtD
Solifenacin—Dizziness—Doxorubicin—muscle cancer	0.0016	0.0016	CcSEcCtD
Solifenacin—Vomiting—Doxorubicin—muscle cancer	0.00153	0.00153	CcSEcCtD
Solifenacin—Rash—Doxorubicin—muscle cancer	0.00152	0.00152	CcSEcCtD
Solifenacin—Dermatitis—Doxorubicin—muscle cancer	0.00152	0.00152	CcSEcCtD
Solifenacin—Headache—Doxorubicin—muscle cancer	0.00151	0.00151	CcSEcCtD
Solifenacin—Nausea—Doxorubicin—muscle cancer	0.00143	0.00143	CcSEcCtD
